Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of -43.89% is 196% below its 5-year average of 45.92%, near the high end of its 5-year range (-1359.24%–100.00%).
88.42% above its 12-month average of -379.08%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
-43.89%
GROSS MARGIN AVG TTM
-379.08%
GROSS MARGIN AVG 3Y
44.03%
GROSS MARGIN AVG 5Y
45.92%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+88.42%
CURRENT VS 3Y AVG
-199.68%
CURRENT VS 5Y AVG
-195.59%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.38%
median of 720 covered companies
CURRENT VS SECTOR MEDIAN
-208.69%
vs the sector median at left
IDEAYA Biosciences, Inc.
Market Cap
$3.54B
Gross Margin
-43.89%
TTM Avg
-379.08%
3Y Avg
44.03%
5Y Avg
45.92%
Market Cap
$3.54B
Gross Margin
71.45%
TTM Avg
69.72%
3Y Avg
68.83%
5Y Avg
69.16%
Market Cap
$3.57B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.43B
Gross Margin
91.13%
TTM Avg
91.57%
3Y Avg
93.72%
5Y Avg
94.38%
Market Cap
$3.43B
Gross Margin
-360.00%
TTM Avg
-180.00%
3Y Avg
-491.57%
5Y Avg
-334.18%
Market Cap
$3.34B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$3.14B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
50.00%
5Y Avg
66.67%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | $3.54B | -43.89% | -379.08% | 44.03% | 45.92% |
| Celcuity Inc. (CELC)vs › | $3.54B | 0.00% | 0.00% | 0.00% | 0.00% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.54B | 71.45% | 69.72% | 68.83% | 69.16% |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.57B | 0.00% | 0.00% | 0.00% | 0.00% |
| CareDx, Inc (CDNA)vs › | $3.45B | 70.58% | 67.35% | 65.86% | 66.29% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.43B | 91.13% | 91.57% | 93.72% | 94.38% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.43B | -360.00% | -180.00% | -491.57% | -334.18% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.34B | 0.00% | 0.00% | 0.00% | 0.00% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.14B | 0.00% | 0.00% | 50.00% | 66.67% |
| ICU Medical, Inc. (ICUI)vs › | $3.98B | 37.56% | 35.69% | 33.68% | 34.73% |
Gross Margin
-43.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | -1359.24% |
| 2025-12-31 | -696.24% |
| 2025-09-30 | 60.07% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 90.81% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 73.90% |
| 2023-09-30 | 87.73% |
| 2023-06-30 | 71.84% |
| 2023-03-31 | 87.82% |
| 2022-12-31 | 86.13% |
| 2022-09-30 | 96.89% |
| 2022-06-30 | 79.42% |
| 2022-03-31 | 95.92% |
| 2021-12-31 | 85.66% |
| 2021-09-30 | -72.72% |
| 2021-06-30 | -71.07% |
| 2021-03-31 | -59.60% |
| 2020-12-31 | 96.58% |
| 2020-09-30 | 96.83% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
